Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93943 | 1.00 | CYP3A4 (0.65) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28535120 | 0.98 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5491525 | 0.98 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3393714 | 0.98 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL6436202 | 0.88 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL388562 | 0.87 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL1581156 | 0.86 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5503979 | 0.86 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL3846866 | 0.86 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL262239 | 0.86 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289951-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| EP-1737819-B1 | AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE | DSM IP ASSETS BV (NL) | 2010-12-22 | — | — | EP | disclosed |
| US-20100168225-A1 | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors | JEAN FRANCOIS | 2010-07-01 | — | — | US | disclosed |
| US-20100099727-A1 | Amino acid and peptide conjugates of arylalkylic acids for cosmetic use | DSM IP ASSETS B.V. (NL) | 2010-04-22 | — | — | US | disclosed |
| US-20080234344-A1 | Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use | DSM IP ASSETS B.V. (NL) | 2008-09-25 | — | — | US | disclosed |
| EP-1737819-A1 | AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE | DSMIP Assets B.V. (NL) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005092850-A1 | AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE | DSM IP ASSETS B.V. (NL) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168225-A1 | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors | SRR, HAVCR2, CBR3 | CYP3A4 73/4885SLC7A5 152/4885HRH4 25/4885 |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | PPM1D, PPM1G, PPM1F | CYP3A4 2191/4885SLC7A5 3768/4885HRH4 1017/4885 |
| US-20080234344-A1 | Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use | NGLY1, HRH4, C3AR1 | CYP3A4 725/4885SLC7A5 48/4885HRH4 2/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | CYP3A4 4184/4885SLC7A5 4451/4885HRH4 4001/4885 |
| US-20100099727-A1 | Amino acid and peptide conjugates of arylalkylic acids for cosmetic use | NGLY1, HRH4, C3AR1 | CYP3A4 725/4885SLC7A5 48/4885HRH4 2/4885 |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, LIPC, HCCS | CYP3A4 1503/4885SLC7A5 4392/4885HRH4 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.